Slide 1: Quantum-Si Corporate Presentation
QUANTUM SI Corporate Presentation @
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations,
Slide 3: Quantum-Si: The Protein Sequencing Company
Quantum-Si: The Protein Sequencing Company™ Founded in 2013; NASDAQ (QSI) since June 2021 Experienced team from life sciences leaders including Illumina, PacBio, and Ion Torrent Launched the world’s first Next-Generation Protein Sequencing™ system, Platinum® in December 2022 Over 1,000 owned and lic
Slide 4: The World's First Next-Generation Protein Sequencer
The World’s First Next-Generation Protein Sequencer™ Unmatched Accessibility List Price <$100K Automated data analysis Addresses gaps in existing genomics and proteomics research workflows Proprietary Technology Kinetic signatures enable single amino acid resolution Single-molecule sensitivity Exten
Slide 5: Company Key Updates
Company Key Updates 2023 Highlights Launched Platinum® in Dec 2022 2024 Guidance Launched V2 sequencing kit in 1Q24 Successfully executed controlled launch, generating $1.1M in revenue Full Commercial Launch initiated 1Q24 Built a world-class leadership team Appointed independent Chairman of BOD Tra
Slide 6: Proteomics Is A Large And Growing Market Opportunity
Proteomics Is A Large And Growing Market Opportunity SVB Leerink Research, “Proteomics: The Next Frontier in Life Science Tools and Diagnostics,” September 28, 2021 DeciBio Consulting Evaluation, June 2020 $75B+ Proteomics Market1 Research $20B+ EmergingClinical $55B+ $8B+ Initial Target Market2 Ide
Slide 7: Proteins Are More Complex And Actionable Than DNA or RNA
Proteins Are More Complex And Actionable Than DNA or RNA 1,000,000+ Proteoforms (Protein) 200,000 Sequences (RNA) 20,000 Genes (DNA) DNA is the blueprint but has limited actionability RNA is more actionable but does not tell the complete story Proteins are extraordinarily diverse and are the real ti
Slide 8: Disease Progression Goes Beyond The Protein Level
Disease Progression Goes Beyond The Protein Level Human Proteoform Project https://www.science.org/doi/10.1126/sciadv.abk0734
Slide 9: Core Areas Of Proteomics Research Today
Core Areas Of Proteomics Research Today HT Affinity Assays Mass Spec EdmanDegradation Western Blots + ELISA Samples: 100s–1,000s per study Proteins: 1000s per sample Resolution: Protein Protein Level Screening Samples: 10s–100s per study Proteins: <50 per sample Resolution: Amino acid; Single-molecu
Slide 10: Deeper Insights With Unprecedented Accessibility
Deeper Insights With Unprecedented Accessibility High-throughput affinity-based assays Mass spec Edman degradation Western blots and ELISA DATA RICHNESS ACCESSIBILITY
Slide 11: The Quantum-Si Solution
The Quantum-Si Solution Sequence Platinum® sequences individual peptides and provides amino acid level resolution Prepare Library Preparation and Sequencing Kits contain everything you need to digest and functionalize proteins and sequence them on our proprietary semiconductor chip Analyze Our analy
Slide 12: Sequence Proteins With Next-Generation Protein Sequencing
Sequence Proteins With Next-Generation Protein Sequencing Sequence Prepare Analyze
Slide 13: The Value of Deeper Insights With Next-Generation Protein Sequencing
The Value of Deeper Insights With Next-Generation Protein Sequencing ProteinEngineering Engineering proteins for therapeutic, industrial, or environmental purposes AntibodyCharacterization Antibody validation isnecessary for research useand drug development DrugDiscovery Studying and screening drug
Slide 14: Differentiating Disease Relevant Proteoforms with Next-Generation Protein Sequencing
Differentiating Disease Relevant Proteoforms with Next-Generation Protein SequencingDr. Gloria Sheynkman lab | Festival of Genomics, ASMS Presented at ASMS 2024 and Festival of Genomics 2024; publication in preparation Different TPM2 isoforms affect bone mineral density, impacting muscle and skeleta
Slide 15: Next-Generation Protein Sequencing is Complementary to Mass Spec in PTM Analysis
Next-Generation Protein Sequencing is Complementary to Mass Spec in PTM AnalysisDr. Neil Kelleher lab | ASMS Pyroglutamate (pE) is a disease-relevant PTM in neurological disease This PTM can also be produced by artifacts in Mass Spectrometry protocols, complicating analyses and producing false-negat
Slide 16: Platinum Complements And Enhances Current Proteomic and Genomic Workflows
Platinum Complements And Enhances Current Proteomic and Genomic Workflows Immunoassays Uncover more than antibodies can with accurate protein identification and amino acid resolution MassSpectrometry Identify proteins with ease and gain deeper insights with single-molecule amino acid level resolutio
Slide 17: Expanding Our Global Commercial Channels + Partnerships
Expanding Our Global Commercial Channels + Partnerships 2024 Commercialization Approach Direct Sales Force Presence Distributor Partner Presence
Slide 18: 2024 Commercial Priorities
2024 Commercial Priorities Build Our Distribution Network Engage with leading life science tools distributors in select regions Expand Our Direct Team Expand direct sales and serviceteam in US and Western Europe Execute on Full Commercial Launch On-site demos to accelerate customer evaluation; Grow
Slide 19: Introducing the Version 3 Sequencing Kit
Introducing the Version 3 Sequencing Kit Enhanced Insights The power of our single-amino acid resolution platform is amplified with the addition of Aspartic acid (D) recognition and improved performance of other recognizers Simplified Workflow Accelerating results with less hands-on time and AI-powe
Slide 20: Delivering on the Innovation Roadmap to Continuously Expand Proteome Coverage
Delivering on the Innovation Roadmap to Continuously Expand Proteome Coverage
Slide 21: V3 Sequencing Kit Offers Increased Output and Value to Customers
V3 Sequencing Kit Offers Increased Output and Value to Customers Amino Acids Sequenced per Chip More than 5.5-fold increase since V1 Cost per 1,000 Amino Acids More than 4.5-fold reduction in cost since V1
Slide 22: Innovation Pipeline is Robust and Accelerating
AUG 24 JAN 24 OCT 22 MAR 23 2H 24 DEC 22 BEYOND JUN 23 Innovation Pipeline is Robust and Accelerating Sequencing V1 V2 V3 V+ Instruments + Software UI/UX ProteinInference AI KineticDatabase V2 AI KineticDatabase V3 Library Prep V+ V1 V2
Slide 23: 2024 Corporate Priorities
2024 Corporate Priorities Accelerate commercial adoption Full commercial launch; Direct and distribution model scale-up;Revenue of $3.7M–4.2M Deliver on our innovation roadmap V2 Kit launched in 1Q24; V3 Kit Launched in 3Q24;Innovation pipeline accelerating; library prep and barcoding kits by YE24 P
Slide 24: Q&A
QUANTUM SI Q&A